Cancer & Immunotherapy: Greatest challenges and novel therapies inspiring European citizens
17 November - 10:00 am - 12:30 pm CET
HOPE joins the FEAM European Biomedical Policy Forum in the organisation – with the support of Cancer Research UK – of the online annual lecture 2020 on “Cancer & Immunotherapy: greatest challenges and novel therapies inspiring European citizens”.
The event will be held on the 17 November 2020, 10 am – 12.30 pm (CET). With a unique European focus on cancer research, the aim of this annual lecture is to discuss progress and new emerging treatments to better manage and eradicate cancer. This event will also explore how policymakers can help to support research into novel therapies, and ensure the newest treatments reach patients across Europe.
On July 2019, the Commissioner for Research, Science and Innovation – Carlos Moedas -officially launched the work on five major European research and innovation missions that will be part of Horizon Europe. These new European R&I missions aim to deliver solutions to some of the greatest challenges facing our world, including cancer. In addition, DG SANTE are producing proposals for Europe’s Beating Cancer Plan, the Commission’s policy agenda to improve cancer control and care.
Cancer is a complex disease in which cells in a specific tissue are no longer fully responsive to the signals within the tissue that regulate cellular differentiation, survival, proliferation and death. As result, these cells accumulate and invade other tissues, causing local damages and inflammation. There are over 200 different types of cancer. In this context, the immuno-oncology is a type of cancer treatment that uses the power of the body’s own immune system to prevent, control, and eliminate cancer. Also known as immunotherapy, this innovative treatment comes in a variety of forms, including targeted antibodies, cancer vaccines, adoptive cell transfer, tumor-infecting viruses, checkpoint inhibitors, cytokines, and adjuvants. Some immunotherapy treatments also use genetic engineering to enhance immune cells’ cancer-fighting capabilities (CAR-T cells).
About the FEAM European Biomedical Policy Forum
The FEAM European Biomedical Policy Forum provides a platform for discussion on key policy issues for the biomedical community. The Forum is an initiative from the Federation of European Academies of Medicine (FEAM). It aims to bring together representatives from academia, research charities, industry, European and national trade associations and professional bodies, regulators, public health bodies, and patient and consumers groups.